Tag Archives: GenomeDx Biosciences

November 2017—GenomeDx Biosciences and Pathnostics announced a strategic agreement for GenomeDx to distribute Pathnostics’ Guidance UGx for urinary tract infections and Guidance PRx for prostatitis. These molecular diagnostic tests detect the genomic sequence of pathogens, providing a faster and more comprehensive solution for physicians and their patients.

August 2017—GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier following the publication of a study in European Urology (Seiler R, et al. Epub ahead of print April 5, 2017) supporting its development and validation. The company believes Decipher Bladder is the first commercially available clinical assay to subtype muscle-invasive bladder cancer with a high degree of accuracy.

ay 2016—GenomeDx Biosciences launched Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis, and cancer-specific death at the time of biopsy in men with prostate cancer.